Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Atopic dermatitis is a chronic inflammatory skin disease often occurring in childhood.
The treatment consists in making daily local treatment with topical steroid on inflammatory lesions and emollient on the whole body. However, approximately 70% of patients do not adhere to therapy.
Studies have shown that this treatment failure is caused by the complexity of the treatment, the time required for its implementation, the cost of treatment, the dosage of the products, fear of side effects or misunderstanding about the chronicity of these diseases inflammatory conditions of the skin.
This study aims to evaluate the consideration of patient preference in the choice of excipient used for the topical treatment of eczema.
Day 0 :
The patient choose the cream it will apply from 4 presented. A total of two bottles will be given to the patient. A bottle containing only the emollient applied to dry areas and another bottle in which 30% will be added Diprosone (topical steroid) to be applied on areas of eczema).
Day 30:
Day 90:
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assess the feasibility of giving the choice to the patient/parent of different galenic in atopic dermatitis. | Assess the feasibility of giving the choice to the patient/parent of different galenic in atopic dermatitis. The primary outcome is evaluated through a questionnaire given to the patient/parent at day 0 day 30 day 90. | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the impact of this procedure in patient adherence to treatment (trough weighing treatments at day 30 and day 90) | 90 days | |
| Evaluate the impact of this procedure on the evolution of the disease | Evaluate the impact of this procedure on the evolution of the disease (trough SCORAD and PO-SCORAD at day 0, day 30, day 90) |
Not provided
Inclusion Criteria:
Patients experiencing treatment failure despite appropriate treatment. Patients minors aged between 3 and 15 years For children age 7 and non-autonomous children in the application of treatment, the parent at the initial consultation should be the one who treats the child.
Information from both parents or parental authority and collection of Non-Opposition The patient must have a computer to do its PO-SCORAD between consultations. Patient who used a topical treatment for atopic dermatitis in the week preceding the study.
Exclusion Criteria:
Patient refusal to participate in the clinical study. Adults and children over 15 years.
Not provided
Not provided
Multicenter prospective nonrandomized uncontrolled open-label study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-François Stalder, PU-PH | Nantes University Hospital | Study Director |
| Jean-Marc Chavigny, PH | Centre Pasteur Dermatologie | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nantes | Nantes | 44093 | France |
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| D000074822 | Treatment Adherence and Compliance |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
Not provided
Not provided
Not provided
| 90 days |
| Assess the feasibility point of view of the prescribing physician | - Assess the feasibility point of view of the prescribing physician (through questionnaires at day 0 day 30 day 90) | 90 days |
| Measuring the characteristics of a specified product and those of a product chosen by the patient | - Measuring the characteristics of a specified product and those of a product chosen by the patient (through questionnaires at day 0, day 30, day 90) | 90 days |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D015438 | Health Behavior |
| D001519 | Behavior |